Bli medlem
Bli medlem

Du är här

2018-01-05

Promore Pharma: Redeye: Promore Pharma - Uncertainty around PXL01 Phase III development in the U.S.

Promore Pharma announced on January 2nd that Cellastra, their intended
partner for the Phase III development of PXL01 in North America, did
not meet their fundraising goal and hence did not opt in on the
collaboration.

Read more and download the Research Update, with a new fair value
range: https://goo.gl/zG8SMY

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/about/

-----------------------------------------------------------
http://news.cision.com/se/promore-pharma/r/redeye-promore-pharma---uncer...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.